Search Results - "ILSON, David"

Advances in the treatment of gastric cancer: 2019 by Ilson, David H

“…PURPOSE OF REVIEWThe aim of this study was to review studies published within the past year regarding management of gastric cancer. RECENT FINDINGSLaparoscopic…”
Get full text

Advances in the treatment of gastric cancer by Ilson, David H

“…PURPOSE OF REVIEWTo review the recent literature regarding treatment of gastric cancer. RECENT FINDINGSAddition of postoperative radiation therapy to…”
Get full text

Management of Patients With Adenocarcinoma or Squamous Cancer of the Esophagus by Ilson, David H., van Hillegersberg, Richard

“…Esophageal cancer is characterized by early and frequent metastasis. Surgery is the primary treatment for early-stage disease, whereas patients with patients…”
Get full text

Adjuvant Nivolumab in Esophageal Cancer — A New Standard of Care by Ilson, David H

“…Esophageal cancer is a leading cause of cancer-related illness and death throughout the world. Because there is no effective screening or early detection, most…”
Get full text

Advances in the treatment of gastric cancer: 2020–2021 by Ilson, David H.

“…PURPOSE OF REVIEWTo review studies from 2020 to 2021 in esophagogastric cancer. RECENT FINDINGSAfter up front D2 gastrectomy for lymph node-positive gastric…”
Get full text

Advances in the treatment of gastric cancer: 2022–2023 by Ilson, David H.

“…PURPOSE OF REVIEWTo review 2022-2023 studies in gastric cancer. RECENT FINDINGSImportant studies report the role of laparoscopic surgery in gastric cancer, the…”
Get full text

Malignancies of the Upper Gastrointestinal Tract by Ilson, David H.

Get full text

Optimal management of gastroesophageal junction cancer by Greally, Megan, Agarwal, Rajiv, Ilson, David H.

“…Although recent decades have witnessed incremental improvements in the treatment of gastroesophageal junction (GEJ) carcinoma, outcomes remain modest. For…”
Get full text

Preoperative chemoradiotherapy or perioperative chemotherapy for patients with gastro-oesophageal junction adenocarcinoma by Ilson, David H, Al-Batran, Salah-Eddin

“…[...]for adenocarcinoma of the oesophagus or gastro-oesophageal junction, there is ongoing debate about the use of chemotherapy alone or combined…”
Get full text

Advances in the treatment of gastric cancer by Ilson, David H.

“…PURPOSE OF REVIEWTo provide an up-to-date review on the management of cancers of the stomach and esophagogastric junction (EGJ). RECENT FINDINGSMicrosatellite…”
Get full text

Advances in the treatment of gastric cancer by Ilson, David H

“…PURPOSE OF REVIEWTo review recent studies in esophagogastric cancer. RECENT FINDINGSPositive emission tomography (PET) scan in follow-up after curative…”
Get full text

Adjuvant therapy in colon cancer: less is more by Ilson, David H

“…The practice-changing results from SCOT need to be taken in the context of the IDEA trial, a pooled analysis of more than 10 000 patients enrolled in six…”
Get full text

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial by Janjigian, Yelena Y, Maron, Steven B, Chatila, Walid K, Millang, Brittanie, Chavan, Shweta S, Alterman, Carly, Chou, Joanne F, Segal, Michal F, Simmons, Marc Z, Momtaz, Parisa, Shcherba, Marina, Ku, Geoffrey Y, Zervoudakis, Alice, Won, Elizabeth S, Kelsen, David P, Ilson, David H, Nagy, Rebecca J, Lanman, Richard B, Ptashkin, Ryan N, Donoghue, Mark T A, Capanu, Marinela, Taylor, Barry S, Solit, David B, Schultz, Nikolaus, Hechtman, Jaclyn F

“…Addition of trastuzumab to first-line chemotherapy improves overall survival in patients with HER2-positive metastatic gastric cancer. We assessed the safety…”
Get full text

Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial by Shitara, Kohei, Doi, Toshihiko, Dvorkin, Mikhail, Mansoor, Wasat, Arkenau, Hendrik-Tobias, Prokharau, Aliaksandr, Alsina, Maria, Ghidini, Michele, Faustino, Catia, Gorbunova, Vera, Zhavrid, Edvard, Nishikawa, Kazuhiro, Hosokawa, Ayumu, Yalçın, Şuayib, Fujitani, Kazumasa, Beretta, Giordano D, Cutsem, Eric Van, Winkler, Robert E, Makris, Lukas, Ilson, David H, Tabernero, Josep

“…Trifluridine/tipiracil showed activity and was well tolerated in a phase 2 study of pretreated patients with advanced gastric cancer done in Japan. We…”
Get full text

Immunotherapy in esophagogastric cancer by Ilson, David H

Get full text

How to use anti-PD-1 therapy in gastric cancer: the approach in the United States by Ilson, David H

“…Gastric cancer is a leading global cause of cancer-related mortality. In the past, survival achieved in metastatic disease with chemotherapy was less than 1…”
Get full text

Angiogenesis in gastric cancer: hitting the target? by Ilson, David H

“…Targeted treatments showing survival benefits in colorectal cancer have not improved survival in gastric cancer, including the vascular endothelial growth…”
Get full text

Neoadjuvant therapy for esophageal cancer: Who, when, and what? by Greally, Megan, Ilson, David H.

“…The perioperative combination of 5‐fluorouracil, oxaliplatin, and docetaxel is a new standard treatment in patients with esophageal carcinoma. However,…”
Get full text

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial by Catenacci, Daniel V T, Tebbutt, Niall C, Davidenko, Irina, Murad, André M, Al-Batran, Salah-Eddin, Ilson, David H, Tjulandin, Sergei, Gotovkin, Evengy, Karaszewska, Boguslawa, Bondarenko, Igor, Tejani, Mohamedtaki A, Udrea, Anghel A, Tehfe, Mustapha, De Vita, Ferdinando, Turkington, Cheryl, Tang, Rui, Ang, Agnes, Zhang, Yilong, Hoang, Tien, Sidhu, Roger, Cunningham, David

“…Rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the MET receptor, hepatocyte growth factor (HGF). We aimed to assess…”
Get full text

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial by Shah, Manish A., Shitara, Kohei, Ajani, Jaffer A., Bang, Yung-Jue, Enzinger, Peter, Ilson, David, Lordick, Florian, Van Cutsem, Eric, Gallego Plazas, Javier, Huang, Jing, Shen, Lin, Oh, Sang Cheul, Sunpaweravong, Patrapim, Soo Hoo, Hwoei Fen, Turk, Haci Mehmet, Oh, Mok, Park, Jung Wook, Moran, Diarmuid, Bhattacharya, Pranob, Arozullah, Ahsan, Xu, Rui-Hua

“…There is an urgent need for first-line treatment options for patients with human epidermal growth factor receptor 2 (HER2)-negative, locally advanced…”
Get full text